US 11118177
Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
granted A61KA61K35/12A61K38/00
Quick answer
US patent 11118177 (Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)) held by CRISPR THERAPEUTICS AG expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K35/12, A61K38/00, A61K48/0066, A61P